サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1695238

血管運動性更年期症状（VMS）治療の世界市場レポート 2025年

Vasomotor Menopausal Symptoms (VMS) Treatment Global Market Report 2025

出版日
ページ情報
英文 200 Pages
納期
2～10営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=143.57円
血管運動性更年期症状（VMS）治療の世界市場レポート 2025年
出版日: 2025年03月04日
発行: The Business Research Company
ページ情報: 英文 200 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

血管運動性更年期症状（VMS）治療市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR6.6％で248億1,000万米ドルに成長します。予測期間の成長は、個別化医療、非ホルモン革新、栄養・食事介入、遠隔医療、デジタルヘルスに起因すると考えられます。予測期間における主な動向には、自然療法や代替療法、植物療法やハーブ療法、更年期障害支援グループ、認知行動療法（cbt）などがあります。

血管運動性更年期症状治療市場の拡大は、更年期人口の増加によって促進されています。更年期は、女性の生殖年齢の終わりを意味する自然な生物学的段階であり、通常45～55歳の間に起こり、平均年齢は51歳前後です。ほてりや膣の乾燥といった症状の治療を求める更年期女性が世界的に増加していることが、血管運動性更年期障害（VMS）治療の成長を促す重要な要因となっています。例えば、米国を拠点とするCuyuna Regional Medical Centerのデータによると、平均寿命の伸びにより、2025年までに11億人の女性が閉経を迎えると推定されています。さらに、閉経人口は2060年まで毎年1.6％増加すると予測されています。したがって、更年期人口層の拡大が血管運動性更年期障害治療市場の成長の原動力となっています。

更年期の女性の健康に焦点を当てた政府の取り組みは、血管運動性更年期障害治療市場の成長を促進します。このような取り組みには、更年期移行期の様々な側面に関する革新的な研究、疾病予防、薬理学的、臨床的、疫学的調査への資金提供が含まれます。このような取り組みは、広範な関心事に取り組む、より広範な女性の健康への取り組みの一部です。一例として、オーストラリアを拠点とする政府機関であるニューサウスウェールズ州政府は、重度の更年期症状を経験する女性を支援することを目的とした最大16の新しいプログラムを設立するために、4年間（2022-2023年から2025-2026年まで）で4,030万米ドルを割り当てています。したがって、更年期の女性の健康に焦点を当てたこうした政府の取り組みが、血管運動性更年期症状治療市場の成長を後押ししています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、コロナ、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

  • 世界血管運動性更年期症状（VMS）治療PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
  • 最終用途産業の分析
  • 世界の血管運動性更年期症状（VMS）治療市場：成長率分析
  • 世界の血管運動性更年期症状（VMS）治療市場の実績：規模と成長, 2019-2024
  • 世界の血管運動性更年期症状（VMS）治療市場の予測：規模と成長, 2024-2029, 2034F
  • 世界血管運動性更年期症状（VMS）治療総アドレス可能市場（TAM）

第6章 市場セグメンテーション

  • 世界の血管運動性更年期症状（VMS）治療市場薬剤クラス別、実績と予測, 2019-2024, 2024-2029F, 2034F
  • 抗うつ薬
  • フルオキセチン
  • パロキセチン
  • セルトラリン
  • ホルモン療法
  • 抗けいれん薬
  • フェニトイン
  • フェノバルビタール
  • その他の薬物クラス
  • 世界の血管運動性更年期症状（VMS）治療市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
  • 病院薬局
  • 小売薬局
  • オンライン薬局
  • その他の流通チャネル
  • 世界の血管運動性更年期症状（VMS）治療市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
  • 病院
  • 専門クリニック
  • ホームケア
  • その他のエンドユーザー
  • 世界の血管運動性更年期症状（VMS）治療市場抗うつ薬の種類別のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
  • SSRI（選択的セロトニン再取り込み阻害薬）
  • SNRI（セロトニン・ノルエピネフリン再取り込み阻害剤）
  • TCA（三環系抗うつ薬）
  • MAOI（モノアミン酸化酵素阻害剤）
  • 非定型抗うつ薬
  • 世界の血管運動性更年期症状（VMS）治療市場フルオキセチンのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
  • うつ
  • 強迫性障害（OCD）
  • パニック障害
  • 全般性不安障害（GAD）
  • 心的外傷後ストレス障害（PTSD）
  • 社会不安障害
  • 月経前不快気分障害（PMDD）
  • 世界の血管運動性更年期症状（VMS）治療市場パロキセチンの種類別のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
  • うつ
  • 強迫性障害（OCD）
  • パニック障害
  • 全般性不安障害（GAD）
  • 心的外傷後ストレス障害（PTSD）
  • 社会不安障害
  • 月経前不快気分障害（PMDD）
  • 世界の血管運動性更年期症状（VMS）治療市場、セルトラリンのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
  • うつ
  • 強迫性障害（OCD）
  • パニック障害
  • 心的外傷後ストレス障害（PTSD）
  • 社会不安障害
  • 月経前不快気分障害（PMDD）
  • 世界の血管運動性更年期症状（VMS）治療市場ホルモン療法の種類別の細分化、実績と予測, 2019-2024, 2024-2029F, 2034F
  • エストロゲン補充療法（ERT）
  • プロゲスチン療法
  • 複合ホルモン療法（CHT）
  • テストステロン補充療法（TRT）
  • 世界の血管運動性更年期症状（VMS）治療市場抗けいれん薬のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
  • ヒダントイン
  • バルビツール酸
  • ベンゾジアゼピン
  • バルプロ酸
  • スクシンイミド
  • カルボン酸誘導体
  • 世界の血管運動性更年期症状（VMS）治療市場、フェニトインのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
  • ヒダントイン
  • 世界の血管運動性更年期症状（VMS）治療市場、フェノバルビタールのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
  • バルビツール酸
  • 世界の血管運動性更年期症状（VMS）治療市場、その他の薬物クラスのタイプ別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
  • 抗生物質
  • 鎮痛剤
  • 抗糖尿病薬
  • 降圧剤
  • 抗凝固剤
  • 免疫抑制剤
  • 抗精神病薬
  • 抗ヒスタミン薬

第7章 地域別・国別分析

  • 世界の血管運動性更年期症状（VMS）治療市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
  • 世界の血管運動性更年期症状（VMS）治療市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

  • 血管運動性更年期症状（VMS）治療市場：競合情勢
  • 血管運動性更年期症状（VMS）治療市場：企業プロファイル
    • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
    • Abbvie Inc. Overview, Products and Services, Strategy and Financial Analysis
    • Novartis AG Overview, Products and Services, Strategy and Financial Analysis
    • Ausio Pharmaceuticals LLC Overview, Products and Services, Strategy and Financial Analysis
    • Teva Pharmaceutical Industries Ltd. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

  • Mylan N.V.
  • Sun Pharmaceutical Industries Ltd.
  • Aurobindo Pharma Limited
  • Kyowa Kirin Co. Ltd.
  • Dr. Reddy's Laboratories Ltd.
  • Alembic Pharmaceuticals Limited Inc.
  • Apotex Inc.
  • Hikma Pharmaceutical plc
  • Endo Pharmaceuticals plc
  • Amneal Pharmaceuticals LLC
  • Mundipharma International Ltd.
  • Lupin Limited
  • Glenmark Pharmaceuticals Ltd.
  • Hisamitsu Pharmaceutical Co. Inc.
  • Zhejiang Huahai Pharmaceutical Co. Ltd.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

  • 血管運動性更年期症状（VMS）治療市場2029：新たな機会を提供する国
  • 血管運動性更年期症状（VMS）治療市場2029：新たな機会を提供するセグメント
  • 血管運動性更年期症状（VMS）治療市場2029：成長戦略
    • 市場動向に基づく戦略
    • 競合の戦略

第36章 付録

目次
Product Code: r29217

Vasomotor menopausal symptoms (VMS) treatment involves medical interventions and therapies aimed at alleviating or managing the range of symptoms associated with menopause. These symptoms, experienced by women during menopause, include hot flashes and night sweats. The treatment approach focuses on rebalancing hormone levels in the body and modifying neurotransmitters in the brain.

The primary categories of medications used in vasomotor menopausal symptoms (VMS) treatment include antidepressants like fluoxetine, paroxetine, and sertraline, hormone therapy, anticonvulsants such as phenytoin and phenobarbital, and others. Antidepressants constitute a class of drugs primarily prescribed to address depression and certain other mental health conditions. These medications are available through various distribution channels, including hospital pharmacies, online pharmacies, and retail pharmacies, catering to different end-users such as hospitals, specialty clinics, and homecare settings.

The vasomotor menopausal symptoms (VMS) treatment market research report is one of a series of new reports from The Business Research Company that provides vasomotor menopausal symptoms (VMS) treatment market statistics, including vasomotor menopausal symptoms (VMS) treatment industry global market size, regional shares, competitors with a vasomotor menopausal symptoms (VMS) treatment market share, detailed vasomotor menopausal symptoms (VMS) treatment market segments, market trends and opportunities and any further data you may need to thrive in the vasomotor menopausal symptoms (VMS) treatment industry. This vasomotor menopausal symptoms (VMS) treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The vasomotor menopausal symptoms (VMS) treatment market size has grown strongly in recent years. It will grow from $17.86 billion in 2024 to $19.19 billion in 2025 at a compound annual growth rate (CAGR) of 7.5%. The growth in the historic period can be attributed to hormone replacement therapy (hrt), menopause awareness, pharmaceutical developments, consumer demand.

The vasomotor menopausal symptoms (VMS) treatment market size is expected to see strong growth in the next few years. It will grow to $24.81 billion in 2029 at a compound annual growth rate (CAGR) of 6.6%. The growth in the forecast period can be attributed to personalized medicine, non-hormonal innovations, nutritional and dietary interventions, telemedicine and digital health. Major trends in the forecast period include natural and alternative approaches, botanical and herbal remedies, menopause support groups, cognitive behavioral therapy (cbt).

The expansion of the vasomotor menopausal symptoms treatment market is fueled by the increasing menopausal population. Menopause, a natural biological phase signifying the end of a woman's reproductive years, typically occurs between the ages of 45 and 55, with an average age of around 51. The growing number of menopausal women worldwide seeking treatment for symptoms like hot flashes and vaginal dryness is a key factor propelling the growth of treatments for vasomotor menopausal symptoms (VMS). For example, data from the Cuyuna Regional Medical Center, a U.S.-based organization, indicates that due to increased life expectancy, an estimated 1.1 billion women will reach menopause by 2025. Additionally, the menopausal population is projected to grow by 1.6% annually until 2060. Hence, the expanding menopausal demographic is a driving force behind the vasomotor menopausal symptoms treatment market's growth.

Government initiatives focused on women's health during menopause are set to drive the growth of the vasomotor menopausal symptoms treatment market. These initiatives encompass funding for innovative research on various aspects of the menopausal transition, disease prevention, and pharmacological, clinical, and epidemiological investigations. Such efforts are part of broader women's health initiatives that address a wide range of concerns. As an illustration, the Government of New South Wales, an Australia-based government agency, has allocated $40.3 million over four years (from 2022-2023 to 2025-2026) to establish up to 16 new programs aimed at assisting women experiencing severe menopausal symptoms. Therefore, these government initiatives focusing on women's health during menopause are propelling the growth of the market for vasomotor menopausal symptoms treatment.

Prominent companies engaged in the vasomotor menopausal symptoms treatment market are prioritizing the development of products like Veozah and securing approvals to offer new treatment alternatives that address unmet medical requirements for patients. The approval of novel drugs for menopausal symptom management presents advantages in terms of improved efficacy and safety compared to existing treatments. For example, in May 2023, Astellas Pharma Inc., a Japan-based pharmaceutical company, received FDA approval for Veozah (fezolinetant) 45 mg, designed to be taken once daily, for the treatment of menopausal vasomotor symptoms (VMS), spanning from mild to severe. Veozah is the first nonhormonal neurokinin 3 (NK3) receptor antagonist authorized for managing menopausal-related VMS. This hormone-free option functions by blocking a neural pathway involved in regulating these symptoms. Veozah provides an alternative treatment choice, particularly for women experiencing such symptoms who either cannot or prefer not to use hormone therapy. The approval of Veozah underscores its potential as a novel drug for addressing menopausal symptoms.

In March 2022, Amyris Inc., a U.S.-based biotechnology firm, acquired MenoLabs LLC for $35.4 million. This acquisition enables Amyris to broaden its presence in the women's health market, gain access to new technologies and capabilities, and acquire a dedicated customer base. MenoLabs LLC, a U.S.-based women's health and technology company, specializes in the development of dietary supplements designed to alleviate menopause symptoms in women.

Major companies operating in the vasomotor menopausal symptoms (vms) treatment market are Pfizer Inc., Abbvie Inc., Novartis AG, Ausio Pharmaceuticals LLC, Teva Pharmaceutical Industries Ltd., Mylan N.V., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Kyowa Kirin Co. Ltd., Dr. Reddy's Laboratories Ltd., Alembic Pharmaceuticals Limited Inc., Apotex Inc., Hikma Pharmaceutical PLC, Endo Pharmaceuticals PLC, Amneal Pharmaceuticals LLC, Mundipharma International Ltd., Lupin Limited, Glenmark Pharmaceuticals Ltd., Hisamitsu Pharmaceutical Co. Inc., Zhejiang Huahai Pharmaceutical Co. Ltd., Emcure Pharmaceuticals Limited, Wockhardt Pvt. Ltd., QuatRx Pharmaceuticals Company, Bionovo Inc., Mithra Pharmaceuticals SA, EndoCeutics Inc., Zydus Group, Edgemont Pharmaceuticals LLC, MenoGeniX Inc., Agile Therapeutics Inc.

North America was the largest region in the vasomotor menopausal symptoms (VMS) treatment market in 2024. The regions covered in vasomotor menopausal symptoms (VMS) treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the vasomotor menopausal symptoms (VMS) treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The vasomotor menopausal symptoms (VMS) treatment market consists of revenues earned by entities by providing services such as cognitive-behavioral therapy, acupuncture, lifestyle modifications, herbal and vitamin supplements and complementary and alternative therapies. The market value includes the value of related goods sold by the service provider or included within the service offering. The vasomotor menopausal symptoms (VMS) treatment market also includes sales of natural supplements, cooling products, vaginal estrogen products, stress-reduction products, sleep aids and dietary supplements. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Vasomotor Menopausal Symptoms (VMS) Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on vasomotor menopausal symptoms (vms) treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for vasomotor menopausal symptoms (vms) treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The vasomotor menopausal symptoms (vms) treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

  • Markets Covered:1) By Drug Class: Antidepressants; Fluoxetine; Paroxetine; Sertraline; Hormone Therapy; Anticonvulsant; Phenytoin; Phenobarbital; Other Drug Classes
  • 2) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy; Other Distribution Channels
  • 3) By End-User: Hospitals; Specialty Clinics; Homecare; Other End-Users
  • Subsegments:
  • 1) By Antidepressants: SSRIs (Selective Serotonin Reuptake Inhibitors); SNRIs (Serotonin-Norepinephrine Reuptake Inhibitors); TCAs (Tricyclic Antidepressants); MAOIs (Monoamine Oxidase Inhibitors); Atypical Antidepressants
  • 2) By Fluoxetine: Depression; Obsessive-Compulsive Disorder (OCD); Panic Disorder; Generalized Anxiety Disorder (GAD); Post-Traumatic Stress Disorder (PTSD); Social Anxiety Disorder; Premenstrual Dysphoric Disorder (PMDD)
  • 3) By Paroxetine: Depression; Obsessive-Compulsive Disorder (OCD); Panic Disorder; Generalized Anxiety Disorder (GAD); Post-Traumatic Stress Disorder (PTSD); Social Anxiety Disorder; Premenstrual Dysphoric Disorder (PMDD)
  • 4) Sertraline: Depression; Obsessive-Compulsive Disorder (OCD); Panic Disorder; Post-Traumatic Stress Disorder (PTSD); Social Anxiety Disorder; Premenstrual Dysphoric Disorder (PMDD)
  • 5) Hormone Therapy: Estrogen Replacement Therapy (ERT); Progestin Therapy; Combined Hormonal Therapy (CHT); Testosterone Replacement Therapy (TRT)
  • 6) Anticonvulsant: Hydantoins; Barbiturates; Benzodiazepines; Valproates; Succinimides; Carboxylic Acid Derivatives
  • 7) Phenytoin: Hydantoins
  • 8) Phenobarbital: Barbiturates
  • 9) Other Drug Classes: Antibiotics; Analgesics; Antidiabetics; Antihypertensives; Anticoagulants; Immunosuppressants; Antipsychotics; Antihistamines
  • Companies Mentioned: Pfizer Inc.; Abbvie Inc.; Novartis AG; Ausio Pharmaceuticals LLC; Teva Pharmaceutical Industries Ltd.
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Vasomotor Menopausal Symptoms (VMS) Treatment Market Characteristics

3. Vasomotor Menopausal Symptoms (VMS) Treatment Market Trends And Strategies

4. Vasomotor Menopausal Symptoms (VMS) Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Vasomotor Menopausal Symptoms (VMS) Treatment Growth Analysis And Strategic Analysis Framework

  • 5.1. Global Vasomotor Menopausal Symptoms (VMS) Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 5.2. Analysis Of End Use Industries
  • 5.3. Global Vasomotor Menopausal Symptoms (VMS) Treatment Market Growth Rate Analysis
  • 5.4. Global Vasomotor Menopausal Symptoms (VMS) Treatment Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
  • 5.5. Global Vasomotor Menopausal Symptoms (VMS) Treatment Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
  • 5.6. Global Vasomotor Menopausal Symptoms (VMS) Treatment Total Addressable Market (TAM)

6. Vasomotor Menopausal Symptoms (VMS) Treatment Market Segmentation

  • 6.1. Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Antidepressants
  • Fluoxetine
  • Paroxetine
  • Sertraline
  • Hormone Therapy
  • Anticonvulsant
  • Phenytoin
  • Phenobarbital
  • Other Drug Classes
  • 6.2. Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • Other Distribution Channels
  • 6.3. Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Hospitals
  • Specialty Clinics
  • Homecare
  • Other End-Users
  • 6.4. Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, Sub-Segmentation Of Antidepressants, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • SSRIs (Selective Serotonin Reuptake Inhibitors)
  • SNRIs (Serotonin-Norepinephrine Reuptake Inhibitors)
  • TCAs (Tricyclic Antidepressants)
  • MAOIs (Monoamine Oxidase Inhibitors)
  • Atypical Antidepressants
  • 6.5. Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, Sub-Segmentation Of Fluoxetine, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Depression
  • Obsessive-Compulsive Disorder (OCD)
  • Panic Disorder
  • Generalized Anxiety Disorder (GAD)
  • Post-Traumatic Stress Disorder (PTSD)
  • Social Anxiety Disorder
  • Premenstrual Dysphoric Disorder (PMDD)
  • 6.6. Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, Sub-Segmentation Of Paroxetine, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Depression
  • Obsessive-Compulsive Disorder (OCD)
  • Panic Disorder
  • Generalized Anxiety Disorder (GAD)
  • Post-Traumatic Stress Disorder (PTSD)
  • Social Anxiety Disorder
  • Premenstrual Dysphoric Disorder (PMDD)
  • 6.7. Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, Sub-Segmentation Of Sertraline, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Depression
  • Obsessive-Compulsive Disorder (OCD)
  • Panic Disorder
  • Post-Traumatic Stress Disorder (PTSD)
  • Social Anxiety Disorder
  • Premenstrual Dysphoric Disorder (PMDD)
  • 6.8. Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, Sub-Segmentation Of Hormone Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Estrogen Replacement Therapy (ERT)
  • Progestin Therapy
  • Combined Hormonal Therapy (CHT)
  • Testosterone Replacement Therapy (TRT)
  • 6.9. Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, Sub-Segmentation Of Anticonvulsant, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Hydantoins
  • Barbiturates
  • Benzodiazepines
  • Valproates
  • Succinimides
  • Carboxylic Acid Derivatives
  • 6.10. Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, Sub-Segmentation Of Phenytoin, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Hydantoins
  • 6.11. Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, Sub-Segmentation Of Phenobarbital, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Barbiturates
  • 6.12. Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, Sub-Segmentation Of Other Drug Classes, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Antibiotics
  • Analgesics
  • Antidiabetics
  • Antihypertensives
  • Anticoagulants
  • Immunosuppressants
  • Antipsychotics
  • Antihistamines'

7. Vasomotor Menopausal Symptoms (VMS) Treatment Market Regional And Country Analysis

  • 7.1. Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 7.2. Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Vasomotor Menopausal Symptoms (VMS) Treatment Market

  • 8.1. Asia-Pacific Vasomotor Menopausal Symptoms (VMS) Treatment Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.3. Asia-Pacific Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.4. Asia-Pacific Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Vasomotor Menopausal Symptoms (VMS) Treatment Market

  • 9.1. China Vasomotor Menopausal Symptoms (VMS) Treatment Market Overview
  • 9.2. China Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.3. China Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.4. China Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Vasomotor Menopausal Symptoms (VMS) Treatment Market

  • 10.1. India Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.2. India Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.3. India Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Vasomotor Menopausal Symptoms (VMS) Treatment Market

  • 11.1. Japan Vasomotor Menopausal Symptoms (VMS) Treatment Market Overview
  • 11.2. Japan Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.3. Japan Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.4. Japan Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Vasomotor Menopausal Symptoms (VMS) Treatment Market

  • 12.1. Australia Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.2. Australia Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.3. Australia Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Vasomotor Menopausal Symptoms (VMS) Treatment Market

  • 13.1. Indonesia Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.2. Indonesia Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.3. Indonesia Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Vasomotor Menopausal Symptoms (VMS) Treatment Market

  • 14.1. South Korea Vasomotor Menopausal Symptoms (VMS) Treatment Market Overview
  • 14.2. South Korea Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.3. South Korea Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.4. South Korea Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Vasomotor Menopausal Symptoms (VMS) Treatment Market

  • 15.1. Western Europe Vasomotor Menopausal Symptoms (VMS) Treatment Market Overview
  • 15.2. Western Europe Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.3. Western Europe Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.4. Western Europe Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Vasomotor Menopausal Symptoms (VMS) Treatment Market

  • 16.1. UK Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.2. UK Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.3. UK Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Vasomotor Menopausal Symptoms (VMS) Treatment Market

  • 17.1. Germany Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.2. Germany Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.3. Germany Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Vasomotor Menopausal Symptoms (VMS) Treatment Market

  • 18.1. France Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.2. France Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.3. France Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Vasomotor Menopausal Symptoms (VMS) Treatment Market

  • 19.1. Italy Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.2. Italy Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.3. Italy Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Vasomotor Menopausal Symptoms (VMS) Treatment Market

  • 20.1. Spain Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.2. Spain Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.3. Spain Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Vasomotor Menopausal Symptoms (VMS) Treatment Market

  • 21.1. Eastern Europe Vasomotor Menopausal Symptoms (VMS) Treatment Market Overview
  • 21.2. Eastern Europe Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.3. Eastern Europe Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.4. Eastern Europe Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Vasomotor Menopausal Symptoms (VMS) Treatment Market

  • 22.1. Russia Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.2. Russia Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.3. Russia Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Vasomotor Menopausal Symptoms (VMS) Treatment Market

  • 23.1. North America Vasomotor Menopausal Symptoms (VMS) Treatment Market Overview
  • 23.2. North America Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.3. North America Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.4. North America Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Vasomotor Menopausal Symptoms (VMS) Treatment Market

  • 24.1. USA Vasomotor Menopausal Symptoms (VMS) Treatment Market Overview
  • 24.2. USA Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.3. USA Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.4. USA Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Vasomotor Menopausal Symptoms (VMS) Treatment Market

  • 25.1. Canada Vasomotor Menopausal Symptoms (VMS) Treatment Market Overview
  • 25.2. Canada Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.3. Canada Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.4. Canada Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Vasomotor Menopausal Symptoms (VMS) Treatment Market

  • 26.1. South America Vasomotor Menopausal Symptoms (VMS) Treatment Market Overview
  • 26.2. South America Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.3. South America Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.4. South America Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Vasomotor Menopausal Symptoms (VMS) Treatment Market

  • 27.1. Brazil Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.2. Brazil Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.3. Brazil Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Vasomotor Menopausal Symptoms (VMS) Treatment Market

  • 28.1. Middle East Vasomotor Menopausal Symptoms (VMS) Treatment Market Overview
  • 28.2. Middle East Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.3. Middle East Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.4. Middle East Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Vasomotor Menopausal Symptoms (VMS) Treatment Market

  • 29.1. Africa Vasomotor Menopausal Symptoms (VMS) Treatment Market Overview
  • 29.2. Africa Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.3. Africa Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.4. Africa Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Vasomotor Menopausal Symptoms (VMS) Treatment Market Competitive Landscape And Company Profiles

  • 30.1. Vasomotor Menopausal Symptoms (VMS) Treatment Market Competitive Landscape
  • 30.2. Vasomotor Menopausal Symptoms (VMS) Treatment Market Company Profiles
    • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.2. Abbvie Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.3. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.4. Ausio Pharmaceuticals LLC Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.5. Teva Pharmaceutical Industries Ltd. Overview, Products and Services, Strategy and Financial Analysis

31. Vasomotor Menopausal Symptoms (VMS) Treatment Market Other Major And Innovative Companies

  • 31.1. Mylan N.V.
  • 31.2. Sun Pharmaceutical Industries Ltd.
  • 31.3. Aurobindo Pharma Limited
  • 31.4. Kyowa Kirin Co. Ltd.
  • 31.5. Dr. Reddy's Laboratories Ltd.
  • 31.6. Alembic Pharmaceuticals Limited Inc.
  • 31.7. Apotex Inc.
  • 31.8. Hikma Pharmaceutical plc
  • 31.9. Endo Pharmaceuticals plc
  • 31.10. Amneal Pharmaceuticals LLC
  • 31.11. Mundipharma International Ltd.
  • 31.12. Lupin Limited
  • 31.13. Glenmark Pharmaceuticals Ltd.
  • 31.14. Hisamitsu Pharmaceutical Co. Inc.
  • 31.15. Zhejiang Huahai Pharmaceutical Co. Ltd.

32. Global Vasomotor Menopausal Symptoms (VMS) Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Vasomotor Menopausal Symptoms (VMS) Treatment Market

34. Recent Developments In The Vasomotor Menopausal Symptoms (VMS) Treatment Market

35. Vasomotor Menopausal Symptoms (VMS) Treatment Market High Potential Countries, Segments and Strategies

  • 35.1 Vasomotor Menopausal Symptoms (VMS) Treatment Market In 2029 - Countries Offering Most New Opportunities
  • 35.2 Vasomotor Menopausal Symptoms (VMS) Treatment Market In 2029 - Segments Offering Most New Opportunities
  • 35.3 Vasomotor Menopausal Symptoms (VMS) Treatment Market In 2029 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer